Warianty tytułu
Języki publikacji
Abstrakty
Evidence suggests that availability of medicines on the Slovak market is both comprehensive and prompt. The low co-payment rate of reimbursed products results in easy access to highly priced patented products. There is always at least one treatment available in determined therapeutic classes with no co-payment. Evidence suggests that Slovak pharmaceutical expenditures do not result in the most cost effective outcomes. The use of HTA in the decision-making process is vague.(original abstract)
Rocznik
Numer
Strony
21--23
Opis fizyczny
Twórcy
autor
- UNION health insurance fund, Bratislava, the Slovak Republic
Bibliografia
- Health Data 2010. Paris, Organisation for Economic Co-operation and Development. Available from: http://www.oecd.org; [Accessed: 27 March 2011]
- Szalay T., Pažitný P., Szalayová A., Frisová S., Morvay K., Petrovič M. and van Ginneken E. Slovakia: Health system review. Health Systems in Transition, 2011; 13(2): 1-200
- Kaló Z., Docteur E., Moïse P. Pharmaceutical pricing and reimbursement policies in Slovakia, OECD Health working paper, 2008
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.ekon-element-000171462658